This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Gilead Sciences, Inc.
Drug Names(s): CAL-101, GS-1101, Idelalisib
Description: CAL-101 is a novel orally-available small molecule inhibitor of the p110(delta) selective phosphoinositide-3 kinase (PI3K). The PI3K pathway stimulates numerous processes that promote cell proliferation, growth, motility, metabolism and survival. While these processes are important for the health of normal cells, inappropriate activation contributes to the development and progression of cancer and immune disorders.
Deal Structure: CAL-101 was originally developed by Calistoga Pharmaceuticals.
In February 2011, Gilead Sciences and Calistoga Pharmaceuticals announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million. Calistoga could earn up to an additional $225 million if certain milestones are achieved. The acquisition was completed in April 2011.
Additional information available to subscribers only: